当前位置: X-MOL 学术Ann. Rheum. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy
Annals of the Rheumatic Diseases ( IF 27.4 ) Pub Date : 2017-09-19 , DOI: 10.1136/annrheumdis-2017-212061
Leonard Calabrese , Xavier Mariette

The rapid introduction of immunotherapies for cancer-targeting immunological checkpoints has led to a new class of toxicities that appear to be of autoimmune and or autoinflammatory origin. These disorders are now referred to as immune-related adverse events (irAEs) and pose considerable challenges to patient care in terms of how to optimally manage these formidable toxicities while allowing effective antitumoural therapy to continue. While rheumatologists will naturally be called on to manage those irAEs of rheumatic origin, we believe there is a need and an opportunity for rheumatologists to participate as central figures in this evolving field, in large part because of our familiarity with multiorgan autoimmune disease and our expertise in crafting and utilising both traditional and biological immune-based therapies. Rheumatologists urgently need education in this evolving field to be best positioned as contributors to care of such patients and investigators of the underlying mechanisms of these complications.

中文翻译:

风湿病学家在管理由癌症免疫疗法引起的免疫相关不良事件 (irAE) 中的作用不断演变

针对癌症的免疫检查点免疫疗法的快速引入导致了一类新的毒性,这些毒性似乎是自身免疫和/或自身炎症起源的。这些疾病现在被称为免疫相关不良事件 (irAE),并且在如何优化管理这些强大的毒性同时允许有效的抗肿瘤治疗继续进行方面对患者护理提出了相当大的挑战。虽然风湿病学家自然会被要求管理那些源自风湿病的 irAE,但我们相信风湿病学家有必要和机会作为这个不断发展的领域的核心人物参与进来,这在很大程度上是因为我们对多器官自身免疫性疾病的熟悉和我们的专业知识在制定和利用传统和生物免疫疗法方面。
更新日期:2017-09-19
down
wechat
bug